PUBLISHER: Grand View Research | PRODUCT CODE: 1511939
PUBLISHER: Grand View Research | PRODUCT CODE: 1511939
The global leadless pacemakers market size is expected to reach USD 1.74 billion by 2030, growing at a CAGR of 15.5% from 2024 to 2030, based on a new report by Grand View Research, Inc. This growth is attributed to technological advancements, rising prevalence of heart diseases, and a preference for minimally invasive procedures. Moreover, the growing aging population globally propels the demand for leadless pacemakers, as bradycardia is common in the geriatric population. According to the Cleveland Clinic, approximately half a million of the geriatric population show the symptoms of bradycardia, thereby driving the industry.
Wireless or leadless pacemakers, frequently used in adult patients, have emerged as a potentially safe and efficient temporary alternative for children experiencing bradycardia, as revealed by research featured in Circulation: Arrhythmia and Electrophysiology, a peer-reviewed journal affiliated with the American Heart Association. This development is expected to be a potential driver for the market growth.
In addition, growing business initiatives by companies for leadless pacemakers propel the industry's growth. For instance, in January 2024, Medtronic plc announced it had received the CE (Conformite Europeenne) Mark for its Micra AV2 and Micra VR2, leadless pacemakers.The Micra AV2 and Micra VR2, which are recognized as the smallest pacemakers globally, offer extended battery life and simplified programming in comparison to earlier models of Micra pacemakers. Despite these advancements, they retain the numerous advantages of leadless pacing, including a reduction in complications when compared to traditional pacemakers.